This clinical trial is focused on studying a disease called Multiple Myeloma, which is a type of cancer that affects the bone marrow. The study is investigating the effectiveness of two treatments: Iberdomide and Isatuximab. Iberdomide is a medication taken in capsule form, while Isatuximab is given as an injection. The purpose of the study is to compare the effects of using Iberdomide alone versus using it in combination with Isatuximab after patients have undergone a procedure called autologous hematopoietic stem-cell transplantation, which is a type of stem cell transplant using the patient’s own cells.
Participants in the study will receive either Iberdomide alone or Iberdomide combined with Isatuximab as maintenance therapy. Maintenance therapy is a treatment given to help keep cancer from coming back after it has been treated. The study will last for up to two years, during which time the researchers will monitor the patients to see how well the treatments work in keeping the cancer from returning. The main goal is to see if the combination of Iberdomide and Isatuximab is more effective than Iberdomide alone in achieving a state called minimal residual disease (MRD) negativity, which means that there are no detectable cancer cells in the bone marrow.
Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to track the effectiveness of the treatments. The study aims to provide valuable information that could improve treatment options for patients with Multiple Myeloma in the future. Participants will be randomly assigned to one of the treatment groups, and some may receive a placebo, which is a substance with no active medication, to help compare the results accurately. The findings from this study could lead to better understanding and management of Multiple Myeloma.
1joining the study
Upon joining the study, the patient will be required to provide written informed consent. This ensures understanding of the trial’s nature and potential consequences.
Eligibility criteria include prior participation in a related trial, a confirmed diagnosis of multiple myeloma, and having undergone specific treatments such as high-dose melphalan therapy and autologous stem cell transplantation.
2initial assessment
An initial assessment will be conducted to confirm the patient’s response to previous treatments and overall health status. This includes evaluating the patient’s performance status and ensuring compliance with the study’s pregnancy prevention program.
3randomization
The patient will be randomly assigned to one of two groups: one receiving iberdomide alone, and the other receiving iberdomide plus isatuximab.
4treatment phase
The treatment phase involves the administration of medications over a two-year period.
Patients in the iberdomide group will take iberdomide orally in capsule form. Dosages may vary, including 1 mg, 0.75 mg, or 0.45 mg, depending on the specific protocol.
Patients in the iberdomide plus isatuximab group will receive iberdomide as described above, along with isatuximab administered as a subcutaneous injection.
5monitoring and follow-up
Throughout the treatment phase, regular monitoring will occur to assess the patient’s response to therapy and any side effects. This includes periodic evaluations of bone marrow to determine minimal residual disease (MRD) status.
Patients will be required to abstain from donating blood and, if applicable, adhere to specific guidelines regarding pregnancy prevention.
6completion of treatment
After two years of maintenance therapy, the treatment phase concludes. Final assessments will be conducted to evaluate the primary endpoint, which is the rate of MRD negativity.
Secondary endpoints, such as progression-free survival, will also be assessed to determine the overall effectiveness of the treatment.
Who Can Join the Study?
Patients must have been part of a previous trial called GMMG-HD8/DSMM XIX, which included a confirmed diagnosis of multiple myeloma with specific symptoms or markers and measurable disease before starting treatment.
Patients must agree not to donate blood while taking the study treatment and for 28 days after stopping the treatment.
Patients must be able to understand the nature and consequences of the clinical trial.
Patients must provide written informed consent before joining the trial.
Patients must have received at least one cycle of high-dose melphalan therapy and autologous stem cell transplantation. Melphalan therapy is a type of chemotherapy, and autologous stem cell transplantation is a procedure where a patient’s own stem cells are used to replace damaged or destroyed bone marrow.
Patients must have shown at least a Partial Response to treatment according to specific criteria at the time of joining the trial. A Partial Response means the disease has improved but is not completely gone.
Patients must be 18 years or older when joining the trial.
Patients must have a WHO performance status of 0, 1, or 2. This status is a measure of a patient’s general well-being and ability to carry out daily activities, with 0 being fully active and 2 being able to do self-care but unable to work.
Females who can have children must have two negative pregnancy tests before starting the study treatment and agree to ongoing pregnancy testing. They must either commit to complete abstinence from heterosexual contact or use two forms of birth control during the study and for 28 days after the last dose of the study drug.
Male participants must practice complete abstinence or use a condom during sexual contact with a pregnant female or a female who can have children while taking the study drug and for 28 days after the last dose, even if they have had a vasectomy.
Males must agree not to donate sperm while on the study treatment and for 28 days after the last dose.
All participants must follow the requirements of the Pregnancy Prevention Program.
Who Cannot Join the Study?
Patients who have a different condition than multiple myeloma cannot participate. Multiple myeloma is a type of cancer that affects certain cells in the bone marrow.
Patients who are not within the specified age range cannot participate. The age range for this study is typically adults.
Patients who are part of a vulnerable population cannot participate. A vulnerable population includes groups like children, pregnant women, or those unable to give consent.
Iberdomide is a medication being studied for its potential to help patients with newly diagnosed multiple myeloma. It is used as a maintenance therapy after patients have undergone a procedure called autologous hematopoietic stem-cell transplantation. The goal of using iberdomide is to reduce the amount of cancer cells remaining in the bone marrow, which is known as minimal residual disease.
Isatuximab is another medication included in the trial, used in combination with iberdomide. Isatuximab is an antibody therapy that targets specific proteins on the surface of cancer cells, helping the immune system to identify and destroy these cells. The combination of isatuximab with iberdomide is being tested to see if it is more effective than using iberdomide alone in achieving better outcomes for patients with multiple myeloma.
Multiple Myeloma – Multiple myeloma is a type of blood cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. These cancerous plasma cells multiply rapidly, leading to an overproduction of abnormal proteins that can cause damage to bones, kidneys, and the immune system. As the disease progresses, it can result in bone pain, fractures, anemia, and increased susceptibility to infections. The accumulation of these abnormal cells can also lead to a decrease in the production of normal blood cells, causing fatigue and other related symptoms. Over time, the disease can cause significant complications, affecting various organs and systems in the body.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Austria 
Germany 
